Sweden
· Delayed Price · Currency is SEK Abera Bioscience AB Statistics
Total Valuation
Abera Bioscience AB has a market cap or net worth of SEK 61.47 million. The enterprise value is 58.84 million.
| Market Cap | 61.47M |
| Enterprise Value | 58.84M |
Important Dates
The next estimated earnings date is Friday, November 8, 2024.
| Earnings Date | Nov 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Abera Bioscience AB has 14.46 million shares outstanding. The number of shares has increased by 13.72% in one year.
| Shares Outstanding | 14.46M |
| Shares Change (YoY) | +13.72% |
| Shares Change (QoQ) | -7.38% |
| Owned by Insiders (%) | 10.45% |
| Owned by Institutions (%) | n/a |
| Float | 12.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.47 |
| PB Ratio | 6.98 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.72 |
| EV / Sales | 6.36 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.80 |
Financial Position
The company has a current ratio of 3.83
| Current Ratio | 3.83 |
| Quick Ratio | 1.48 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6,480.50 |
Financial Efficiency
Return on equity (ROE) is -98.58% and return on invested capital (ROIC) is -63.25%.
| Return on Equity (ROE) | -98.58% |
| Return on Assets (ROA) | -47.08% |
| Return on Capital (ROIC) | -63.25% |
| Revenue Per Employee | 1.54M |
| Profits Per Employee | -1.27M |
| Employee Count | 6 |
| Asset Turnover | 0.89 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9.54% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +9.54% |
| 50-Day Moving Average | 4.37 |
| 200-Day Moving Average | 4.83 |
| Relative Strength Index (RSI) | 50.57 |
| Average Volume (20 Days) | 4,435 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Abera Bioscience AB had revenue of SEK 9.26 million and -7.63 million in losses. Loss per share was -0.54.
| Revenue | 9.26M |
| Gross Profit | 9.26M |
| Operating Income | -7.83M |
| Pretax Income | -7.63M |
| Net Income | -7.63M |
| EBITDA | n/a |
| EBIT | -7.83M |
| Loss Per Share | -0.54 |
Balance Sheet
| Cash & Cash Equivalents | 2.63M |
| Total Debt | n/a |
| Net Cash | 2.63M |
| Net Cash Per Share | 0.18 |
| Equity (Book Value) | 8.80M |
| Book Value Per Share | 0.61 |
| Working Capital | 6.51M |
Cash Flow
In the last 12 months, operating cash flow was -11.85 million and capital expenditures -419,000, giving a free cash flow of -12.26 million.
| Operating Cash Flow | -11.85M |
| Capital Expenditures | -419,000 |
| Free Cash Flow | -12.26M |
| FCF Per Share | -0.85 |
Margins
Gross margin is 100.00%, with operating and profit margins of -84.58% and -82.39%.
| Gross Margin | 100.00% |
| Operating Margin | -84.58% |
| Pretax Margin | -82.39% |
| Profit Margin | -82.39% |
| EBITDA Margin | n/a |
| EBIT Margin | -84.58% |
| FCF Margin | -132.51% |
Dividends & Yields
Abera Bioscience AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.72% |
| Shareholder Yield | -13.72% |
| Earnings Yield | -12.73% |
| FCF Yield | -19.95% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |